Academic Journal
Q1AIDS
About AIDS
AIDS is a scholarly journal published by Lippincott Williams and Wilkins. SCImago 2025 lists it in Q1, with an SJR of 1.141 and H-index of 237.
Coverage: 1987-2026. Research categories: Infectious Diseases (Q1); Immunology (Q2); Immunology and Allergy (Q2).
Source-backed journal facts
Topics in published research
HIV Research and Treatment; HIV/AIDS Research and Interventions; HIV/AIDS drug development and treatment; HIV-related health complications and treatments; Adolescent Sexual and Reproductive Health; HIV, Drug Use, Sexual Risk.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Cognitive trajectories in HIV: looking beyond the virus to preserve brain health
Jaime H. Vera
2026-11 · DOI: 10.1097/qad.0000000000004601Persistent injection-site nodules visible on cross-sectional imaging: clinical experience with injectable lenacapavir and review of the literature
Stephen P. Connolly, Alan Winston, Borja Mora Peris, Siraj Yusuf et al.
2026-11 · DOI: 10.1097/qad.0000000000004590HIV-associated pulmonary arterial hypertension: improving survival despite persistent treatment gaps – a systematic review and meta-analysis
Marcos Vinicius Fernandes Garcia, Tim Lahm
2026-11 · DOI: 10.1097/qad.0000000000004595Real-life durability and virological outcomes of doravirine in people with multidrug-resistant HIV
Tommaso Clemente, Nicolò Capra, Vincenzo Malagnino, Riccardo Lolatto et al.
2026-11 · DOI: 10.1097/qad.0000000000004574An inclusive approach for developing global clinical trial recommendations
Victoria O. Kasprowicz, Steven G. Deeks, William Kilembe, Krista L. Dong et al.
2026-11 · DOI: 10.1097/qad.0000000000004582Can low-burden HIV pre-exposure prophylaxis become affordable in low- and middle-income countries?
Iulia Filip
2026-11 · DOI: 10.1097/qad.0000000000004626Cancer incidence and risk factors among people with HIV in REPRIEVE
Sophia Zhao, Sara McCallum, Aya Awwad, Philip E. Castle et al.
2026-09-18 · DOI: 10.1097/qad.0000000000004625Retention in care: is it still a clinically useful indicator for monitoring long-term engagement in HIV care in the treat-all era?
Sita Lujintanon, Peter F. Rebeiro, Keri N. Althoff, Joyce L. Jones et al.
2026-09-18 · DOI: 10.1097/qad.0000000000004623Effects of semaglutide on subclinical cardiovascular health in people with HIV
Joviane Daher, Ziad Koberssy, Nicolas Moussallem, Qian Wu et al.
2026-09-17 · DOI: 10.1097/qad.0000000000004624Antiretroviral therapy regimens initiated during pregnancy and risks of adverse perinatal outcomes
Basma N. Dib, Rebecca Zash, Sean Brummel, Modiegi Diseko et al.
2026-09-11 · DOI: 10.1097/qad.0000000000004620Does where you live matter? Rurality and 30-day hospital readmission among people with HIV
Michael O. Budu, Katherine W. Kooij, Ravnit Dhinsa, Taylor McLinden et al.
2026-09-09 · DOI: 10.1097/qad.0000000000004619Circulating markers of organ damage associate with COPD in people with HIV: an exploratory proteomic analysis
Lennart Riemann, Lena Böger, Carina Dahl, Timo Gemoll et al.
2026-09-03 · DOI: 10.1097/qad.0000000000004618Cardiovascular risk prediction in people with HIV: looking beyond low-density lipoprotein cholesterol
Iulia Filip
2026-11 · DOI: 10.1097/qad.0000000000004612Clinical phenotypes and incidence of acute or recent hepatitis C virus infection and bacterial sexually transmitted infections among MSM with HIV
Juan Berenguer, Pablo Ryan, Luis Ramos-Ruperto, Luz Martín-Carbonero et al.
2026-09-02 · DOI: 10.1097/qad.0000000000004614Sex-modulated associations between cytomegalovirus cell-associated DNA and cognition in people with HIV on ART
Alfonso Cabello-Ubeda, Patricia K. Riggs, Gordon Honerkamp-Smith, Alan Wells et al.
2026-09-02 · DOI: 10.1097/qad.0000000000004617Efficacy of dolutegravir or bictegravir-containing therapy in a real-life cohort of people with HIV-1 sub-subtype A6
Miłosz Parczewski, Maurizio Zazzi, Kaja Mielczak, Micha Böhm et al.
2026-09-02 · DOI: 10.1097/qad.0000000000004610LDL-C target achievement in people living with HIV: impact of combination lipid-lowering therapy. A retrospective cohort analysis
Marcella Manicardi, Jovana Milic, Giuseppe Esposito, Marianna Menozzi et al.
2026-08-31 · DOI: 10.1097/qad.0000000000004594Rethinking HIV resistance in the era of long-acting therapy: from isolated events to durable exposure
Luis Buzón, Enrique Bernal-Morell, Marisa Luisa Montes, Laura Gisbert et al.
2026-10 · DOI: 10.1097/qad.0000000000004581The additive value of coronary calcium in identifying cardiovascular risk in ageing people with HIV
Maithili Varadarajan, Ruth Byrne, Abethale Al-Hussaini, Brian Halliday et al.
2026-10 · DOI: 10.1097/qad.0000000000004514Long-term effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and resistance-associated mutations
Cinthia S. Lamaizón, Diego Cecchini, Martin Brizuela, Gastón Copertari et al.
2026-10 · DOI: 10.1097/qad.0000000000004553Reviews
Community Reviews
Version History
October 4, 2026 at 8:56 pm
September 25, 2026